Valo Health

Valo Health combines human-centric data, AI, and computation through its Opal Computational Platform to accelerate drug discovery and development across the full pipeline. The company integrates clinical, genomic, and real-world evidence datasets with machine learning to identify novel targets, design molecules, and optimize clinical development strategies. Valo has a major expanded collaboration with Novo Nordisk worth up to $4.6B in potential milestones for cardiometabolic diseases.

$300M+

Total raised

Opal Computational Platform integrates patient-level clinical, genomic, and real-world evidence data with AI to discover novel drug targets, design therapeutic candidates, and optimize clinical trial strategies. The platform supports end-to-end drug development from target identification through clinical readout.